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Introduction 
Holistic therapy is becoming a national trend and a lot of people are turning to marijuana for its 
potential benefits. Even pregnant women are using marijuana to manage nausea and vomiting. 1 
Currently, medical marijuana is legal in 33 states and the District of Columbia, with 10 states 
also legalizing its recreational use. 1 In the US, between 16.2% of pregnant women are using 
marijuana daily.2 In a study surveying 785 pregnant women, 79% reported perceiving little to no 
harm in prenatal marijuana use.3 Due to the increase in its use and the common perception of 
being harmless, it is important that we determine whether there is an association between adverse 
fetal outcomes and marijuana use during pregnancy.  
Studies have shown a correlation between neurodevelopment disruption, decreased birth weight, 
and increased NICU admissions with prenatal marijuana use. 1,4 However other recent studies 
have shown no significant impact on fetal growth, rates of stillbirth and preterm delivery, or 
congenital malformations.5,6 One study concluded that there is a significantly lower proportion of 
infants admitted to the NICU compared to nonusers.6 In a recently reported California study 
comparing 2,890,555 mothers who used opioid, cocaine, cannabis, amphetamine, other, or 
polysubstance showed that mothers with reported drug abuse/dependence during pregnancy were 
at an increased risk of having a preterm birth and all groups except those using cannabis were at 
risk of having an early term birth. 7 
It is apparent that studies on the effects of prenatal exposure to marijuana have conflicting results 
and conclusions.4 However, the American College of Obstetricians and Gynecologists(ACOG) 
released guidelines in 2017 advising physicians to inquire about marijuana use in pregnant and 
breastfeeding mothers and encourage them to discontinue use.8 It is difficult to know whether 
marijuana is independently responsible for negative birth outcomes considering tobacco, 
nutrition, stress and other factors also have an effect on birth outcome and are heavily associated 
with prenatal marijuana use.9 
With prenatal marijuana use being on the rise, physicians could benefit from well designed 
studies assessing the effects of prenatal exposure to marijuana in humans. This retrospective 
study aims to investigate the birth outcomes of neonates born to mothers who used marijuana 
during their pregnancy and compare to those women who used other prenatal illicit drugs with 
and without marijuana as well as women who did not use illicit drugs at all. The results of this 
study may be useful for future research on the benefits and harms associated with prenatal 
marijuana use. 
 
 
Methods 
This is a retrospective cohort study comparing outcomes of prenatal marijuana use. We looked at 
two groups of mothers: mothers using marijuana alone and mothers using nothing (our control 
group). This investigation will also attempt to discover any trends or correlations between birth 
outcomes and biological factors like sex, race, and maternal comorbidities. The study will 
include extraction of medical records from EPIC, the Premier Health electronic medical record, 
for all mothers ages 18 to 40 years old who delivered at Miami Valley hospital between 2012 
and 2017.  
The data were analyzed with SPSS version 25. We used a chi square test for categorical data 
such as respiratory distress, jaundice, sepsis, necrotizing enterocolitis, NICU admission, sex, 
race, still birth, congenital birth defects, breastfeeding issues, maternal race, maternal diabetes or 
preeclampsia, and drugs used by mom. We t-test for birth weight, gestation age at delivery, 
NICU length of stay, preterm delivery age, NAS score, APGAR score at 1 minute and 5 minutes, 
maternal age, and maternal gravida and parity.  
Since prenatal marijuana use is illegal, it is best to approach this topic by reviewing the 
healthcare system database rather than addressing mothers directly. Data were stored on a 
Premier drive which requires unique usernames and passwords. PHI such as admission dates and 
discharge dates were converted to length of stay, and birth date was converted to age, so actual 
dates could be removed from the dataset prior to analysis. Only members of the study team had 
access to the electronic research records. MRN and patient name were needed to match records, 
but once matched, they were removed from the dataset and replaced with a patient research ID 
number. Only the PI had access to the Key connecting the patient research ID and MRN. 
Miami Valley Hospital delivers about 4,000 babies per year. If the US prenatal marijuana use has 
an 11% prevalence, this will provide us with an experimental group of at least 2,200 mothers 
over a 5 year time span. This will provide enough information to conduct an exploratory 
analysis.  
Inclusion criteria are: women, minimum of 18 years old, maximum of 40 years old, delivered at 
Miami Valley Hospital between 2012 and 2017. 
Results 
Demographics 
In all, 499 patients from Miami Valley Hospitals records were reviewed. Less than one fourth of 
the mothers tested positive for THC at delivery. Table 1 shows the base characteristics of the 
two study groups, control and THC. The control group(n=386) included more mothers than the 
THC group(n=113). The median ages for the control group and THC group were 24 and 25 years 
old, respectively. Most of the patients included in the study were African American, 95%. 
Interestingly, only 4% of the THC self-reported drug use and 4% of the control group also self-
reported drug use. Gravida(p=.01), para(p=.01), race(.03), and tobacco use(p<.01) showed 
statistically significant differences. 
 
 
 
 
 
 
Neonatal Outcomes 
When comparing the groups’ neonatal outcomes, living, fetal demise, meconium, 
polyhydramnios, and decreased variability cases were higher in the control group but were not 
statistically significant. Table 2 shows data for all neonatal outcomes.  The BMI and average 
NAS score were significantly different between the two groups(p=.03 and p=.04 respectively). 
NICU admissions, jaundice, necrotizing enterocolitis, respiratory distress syndrome, feeding 
Table 1: Demographics 
 Control THC p value 
Mother’s age 24.94±4.89 
 
25.7±5.12 
 
0.15 
 
Gravida 2.98±1.98 
 
3.55±2.26 
 
0.01 
 
Para 1.26±1.40 
 
1.65±1.35 
 
0.01 
 
African American 59.1%(295) 
 
19.0%(95) 
 
0.03 
 
Caucasian 18.0%(90) 
 
3.4%(17) 
 
0.03 
 
Bi-racial .2%(1) 
 
0% 
 
0.03 
 
Unreported Race 0% 
 
.2%(1) 
 
0.03 
 
Male Neonate 39.7%(198) 
 
11.8%(59) 
 
0.85 
 
Female Neonate 37.5%(187) 
 
10.8%(54) 
 
0.85 
 
Neonate Gender 
Unknown 
.2%(1) 
 
0% 
 
0.85 
 
Medicaid/Medicare 70.1%(350) 
 
20.6%(103) 
 
0.87 
 
Private Insurance 6.8%(34) 
 
1.8%(9) 
 
0.87 
 
Uninsured .4%(2) 
 
.2%(1) 
 
0.87 
 
Reported alcohol 
use 
.4%(2) 
 
.2%(1) 
 
0.55 
 
Reported drug use 3%(15) 
 
1%(5) 
 
0.79 
 
Reported tobacco 
use 
17.4%(87) 
 
9.8%(49) 
 
 <.001 
problems, sepsis, and acidosis were included in the original data set but showed no cases for 
either groups. 
Maternal Outcomes 
There was more hypertension, preeclampsia (severe and mild), gestational diabetes, and 
complicated diabetes amongst the control group and more placental abruption in the THC group 
(Table 3). The increase in cases of hypertension in the control group was the only outstanding 
maternal outcome that showed statistical significance (p = <.001). More than 85% of the 
hypertension cases were in the control group while the THC group made up less than 15% of the 
cases. Eclampsia, embolus, hemorrhage, placenta previa, prolonged labor, prolonged 2nd stage, 
uterine tachysystole, and HELLP were included in the original data set but showed no cases for 
either groups. 
Table 2: Neonatal Outcomes 
 Control THC p value 
Fetal Demise 16.3% (8) .4% (2) 0.77 
Neonatal Demise .4% (2) 0% 0.77 
Living 74.5% (372) 22.2% (111) 0.77 
BMI (latest) 33.951±8.2195 31.838±7.5467 0.03 
Meconium  2.4% (12) .2% (1) 0.1 
Oligohydramnios .2% (1) .4% (2) 0.19 
Polyhydramnios .6% (3) 0% 0.56 
Multiple Late 
Decels 
1% (5) .4% (2) 1 
Extended Fetal 
Bradycardia 
.2% (1) .2% (1) 0.49 
Decreased 
Variability 
1.2% (6) 0% 0.18 
APGAR at 1 
minute* 
7.44±1.977 7.58±1.674 
 
0.5 
 
APGAR at 5 
minutes* 
8.64±1.504 8.77±1.044 
 
0.42 
 
Length of Stay 3±3.576 2.7±1.117 
 
0.38 
 
NAS (highest 
score)** 
4.82±3.621 
 
6.33±1.528 
 
0.49 
 
NAS (average 
score)** 
3.1418±2.34139 
 
6.1667±1.75594 
 
0.04 
 
Chorioamnionitis 1.4% (7) .8%(4) 
 
0.5 
 
*APGAR: Appearance, Pulse, Grimace, Activity, and Respiration 
**NAS: Neonatal Abstinence Score 
 
Table 3: Maternal Outcomes 
 Control THC p value 
Gestational 
Diabetes 
2.2%(11) 
 
.2%(1) 
 
0.19 
Complicated 
Diabetes 
.6%(3) 
 
0% 1 
Placental 
Abruption 
0% 
 
.6%(3) 0.02 
Precipitous 
Labor 
.2%(1) 
 
0% 1 
Preeclampsia 1%(5) 
 
.8%(4) 0.27 
Mild 
Preeclampsia 
2.2%(11) 
 
.6%(3) 1 
Severe 
Preeclampsia 
8.4%(42) 
 
1.6%(8) 0.2 
Premature 
Rupture of 
Membrane 
.6%(3) 
 
1%(5) 0.04 
Uterine 
Rupture 
.2%(1) 
 
0% 1 
Hypertension 26.7%(133) 
 
4.2%(21) <.001 
    
 
Discussion 
We carried out a retrospective cohort study comparing the outcomes of prenatal marijuana use. 
Previous studies have shown conflicting results and lack of well-designed studies making it 
difficult to reach a finite conclusion about the effects of prenatal marijuana use. The only 
statistically significant difference between the two groups in neonatal outcomes was average 
NAS score which was higher in the THC group. Literature states that a large portion of 
marijuana users go on to use other illegal drugs. 10 This could explain why the THC group has a 
higher average NAS score in comparison to the control group. Although our study did not 
include mothers who tested positive at delivery for any other drug in addition to marijuana in the 
THC group, this does not mean that the mothers studied were not using opiates or other illegal 
drugs during the duration of their pregnancy and contribute to birth outcomes. Feeding 
complications, HELLP, jaundice, necrotizing enterocolitis (NEC), neonatal intensive care unit 
(NICU) admissions, and respiratory distress syndrome(RDS), sepsis, and acidosis were reviewed 
in addition to neonatal outcomes listed in Table 2 but there were no cases for either groups thus 
removed from the final data set. However, the results of this exploratory study did show notably 
more cases of hypertension, mild and severe preeclampsia, and gestational diabetes in the control 
group compared to the THC group, with a statistical significance in regards to hypertension. The 
finding that the control group had more hypertension cases is intriguing and unexpected. A 
possible explanation is that THC has vasodilatory effects resulting in protection from common 
cardiovascular and peripheral vasculature pathologies in pregnancy. Available literature shows 
that THC increases peripheral vasculature resistance, heart rate, and cardiac output in humans 
while causing bradycardia and hypotension in animals which is inconsistent with our findings. 
11,12 There is little data speaking to the effects of marijuana on metabolic processes but available 
data states that THC decreases fasting plasma glucose and improves pancreatic β cell function. 13 
Our findings of higher BMI and more cases of gestational diabetes in the control group are 
consistent with this conclusion. A major strength of this study is that the THC group was created 
by positive urine drug screen at delivery rather than self-reported use like in most available 
studies. This study also has several limitations. Selection bias was likely as we limited the 
sample size to 500, meaning all patients who had the appropriate inclusion criteria were not 
included in the study. The sample size was limited to 500 due to purpose of this study being an 
exploratory study which limited generalizability. Most of the mothers studied were African 
American which also limits generalizability across races. There were also more patients in the 
control group(n=386) than the THC group(n=113) which makes it confusing to know whether 
the results that were significantly higher in the control group (hypertension, gestational diabetes, 
and mild and severe preeclampsia) were truly because of the lack of THC or because of higher 
number of participants. Due to the retrospective nature of the study, we were not able to adjust 
data for confounding factors. Mothers in the control group did not test positive for any illicit 
drug use at delivery but this does not mean that the mothers did not participate in illicit drug use 
at any point in time during the duration of the pregnancy. To effectively measure the neonatal 
outcomes of prenatal marijuana, future research needs to include a prospective study with a 
larger, diverse sample in mothers with similar demographics and equal number of mothers in 
each group while eliminating confounding factors. This was a pilot study conducted to help 
understand the prenatal marijuana use at Miami Valley Hospital and respective neonatal 
outcomes as well as to assist with generating a hypothesis for future studies. In conclusion, this 
study showed significantly higher average NAS scores in neonates born to mothers who tested 
positive for marijuana use at delivery and significantly higher rates of hypertension in mothers 
who did not.   
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